Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company
Transaction validates dual-payload ADC platform and reinforces Linden Lake Labs’ life sciences platform for advancing breakthrough therapies
Xcellon Biologics Launches Xcellerate Program to Support Early-Stage Biotech Innovation
Rockville, MD — February 20, 2026 The Xcellerate biotech program from Xcellon Biologics was created to help early-stage companies navigate one of the most difficult phases of development. By providing structured technical support in Antibody Drug Conjugate development, CMC planning, and early decision-making strategy, the program enables startups to generate meaningful data and move forward […]
IntoCell and Xcellon Biologics Partner to Expand Access to Next-Generation ADC Technologies
Daejeon, South Korea and Rockville, MD — October 31, 2025 Xcellon Biologics, a leading Antibody Drug Conjugate CDMO, announced a new partnership with IntoCell Inc. (KOSDAQ: 287840) to expand access to next-generation ADC linker-payload technologies. The collaboration combines IntoCell’s proprietary OHPAS platform with Xcellon’s ADC process development and manufacturing expertise to help innovators advance differentiated […]
Antibody Drug Conjugate CDMO Xcellon partners with Invenra
Rockville, MD — October 22, 2025 Xcellon Biologics, an Antibody Drug Conjugate (ADC) CDMO, announced a new collaboration with Invenra Inc. to accelerate multispecific ADC programs. The partnership combines Invenra’s discovery platforms with Xcellon’s expertise in bioconjugation, process development, and GMP-ready manufacturing. Together, the companies aim to advance the next generation of targeted therapeutics. Read […]
TEDCO Equitech Growth Fund awarded Xcellon Biologics
Rockville MD — October 22 2025 Xcellon Biologics announced that it has received a $990,000 award from the TEDCO Equitech Growth Fund to accelerate the expansion of its antibody drug conjugate (ADC) biomanufacturing facility in Rockville, Maryland. The investment is part of the second round of Equitech Growth Fund awards that support inclusive growth across […]
From Global Pharma to Maryland’s Next-Gen CDMO: Yuk Chun Chiu’s Vision for Xcellon Biologics
With Xcellon Biologics, a Maryland CDMO focused on antibody-drug conjugates and advanced biologics, industry veteran Yuk Chun Chiu is betting on the state’s rising biotech hub to shape the future of complex therapeutics. Global Career, Full Circle in Maryland Chiu’s career began in Rockville with Human Genome Sciences before taking him to leadership roles at […]
Xcellon Biologics’ Modular Fc Glycan Conjugation: Unlocking Next-Generation Antibody Therapeutics
Introduction The therapeutic antibody field continues to evolve with modalities such as ADCs, ISACs, AOCs, and RLTs. To meet their precision needs, Xcellon Biologics has developed a modular Fc glycan conjugation platform that delivers highly uniform and stable antibody conjugates at scale. Traditional cysteine- and lysine-based conjugation approaches, while widely used, often introduce heterogeneity, stability […]
